301 related articles for article (PubMed ID: 26795874)
1. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.
Henderson EJ; Lord SR; Brodie MA; Gaunt DM; Lawrence AD; Close JC; Whone AL; Ben-Shlomo Y
Lancet Neurol; 2016 Mar; 15(3):249-58. PubMed ID: 26795874
[TBL] [Abstract][Full Text] [Related]
2. The ReSPonD trial--rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen.
Henderson EJ; Lord SR; Close JC; Lawrence AD; Whone A; Ben-Shlomo Y
BMC Neurol; 2013 Dec; 13():188. PubMed ID: 24299497
[TBL] [Abstract][Full Text] [Related]
3. [Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].
Amadori K
Z Gerontol Geriatr; 2016 Oct; 49(7):662-663. PubMed ID: 27599816
[No Abstract] [Full Text] [Related]
4. Cholinesterase inhibitor to prevent falls in Parkinson's disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson's disease.
Neumann S; Taylor J; Bamford A; Metcalfe C; Gaunt DM; Whone A; Steeds D; Emmett SR; Hollingworth W; Ben-Shlomo Y; Henderson EJ
BMC Neurol; 2021 Oct; 21(1):422. PubMed ID: 34715821
[TBL] [Abstract][Full Text] [Related]
5. Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson's: the PDSAFE RCT.
Ashburn A; Pickering R; McIntosh E; Hulbert S; Rochester L; Roberts HC; Nieuwboer A; Kunkel D; Goodwin VA; Lamb SE; Ballinger C; Seymour KC
Health Technol Assess; 2019 Jul; 23(36):1-150. PubMed ID: 31339100
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
8. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
Moreau C; Delval A; Defebvre L; Dujardin K; Duhamel A; Petyt G; Vuillaume I; Corvol JC; Brefel-Courbon C; Ory-Magne F; Guehl D; Eusebio A; Fraix V; Saulnier PJ; Lagha-Boukbiza O; Durif F; Faighel M; Giordana C; Drapier S; Maltête D; Tranchant C; Houeto JL; Debû B; Sablonniere B; Azulay JP; Tison F; Rascol O; Vidailhet M; Destée A; Bloem BR; Bordet R; Devos D;
Lancet Neurol; 2012 Jul; 11(7):589-96. PubMed ID: 22658702
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study.
Mamikonyan E; Xie SX; Melvin E; Weintraub D
Mov Disord; 2015 Jun; 30(7):912-8. PubMed ID: 25914281
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors for Parkinson's disease dementia.
Maidment I; Fox C; Boustani M
Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
[TBL] [Abstract][Full Text] [Related]
13. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial.
van Eijk MM; Roes KC; Honing ML; Kuiper MA; Karakus A; van der Jagt M; Spronk PE; van Gool WA; van der Mast RC; Kesecioglu J; Slooter AJ
Lancet; 2010 Nov; 376(9755):1829-37. PubMed ID: 21056464
[TBL] [Abstract][Full Text] [Related]
14. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
[TBL] [Abstract][Full Text] [Related]
16. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial.
Devos D; Moreau C; Maltête D; Lefaucheur R; Kreisler A; Eusebio A; Defer G; Ouk T; Azulay JP; Krystkowiak P; Witjas T; Delliaux M; Destée A; Duhamel A; Bordet R; Defebvre L; Dujardin K
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):668-74. PubMed ID: 24218528
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
McGarry A; Rosanbalm S; Leinonen M; Olanow CW; To D; Bell A; Lee D; Chang J; Dubow J; Dhall R; Burdick D; Parashos S; Feuerstein J; Quinn J; Pahwa R; Afshari M; Ramirez-Zamora A; Chou K; Tarakad A; Luca C; Klos K; Bordelon Y; St Hiliare MH; Shprecher D; Lee S; Dawson TM; Roschke V; Kieburtz K
Lancet Neurol; 2024 Jan; 23(1):37-45. PubMed ID: 38101901
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine: in Parkinson's disease dementia.
Siddiqui MA; Wagstaff AJ
CNS Drugs; 2006; 20(9):739-47; discussion 748-50. PubMed ID: 16953649
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine for minor visual hallucinations in Parkinson's disease: A randomized controlled trial with 24 months follow-up.
van Mierlo TJM; Foncke EMJ; Post B; Schmand BA; Bloem BR; van Harten B; Tissingh G; Munts AG; de Haan RJ; de Bie RMA;
Brain Behav; 2021 Aug; 11(8):e2257. PubMed ID: 34291590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]